CISPOLY
Guarding women's health through innovative epigenetic technology
A pioneer in early screening & diagnosis of gynecologic tumors
Advancing DNA methylation technology to break new ground in non-invasive early detection.
Founded in 2020 and headquartered in the Beijing Daxing Biomedical Industry Base, CISPOLY is a technology-driven enterprise dedicated to advancing health through innovation. As a pioneer in early screening and diagnosis of gynecologic cancers, CISPOLY is a certified National and Zhongguancun High-Tech Enterprise, focusing on the R&D, manufacturing, and commercialization of early screening and diagnostic products for women's cancers and related diseases, along with automated testing equipment.
Driven by innovative technology
Our Journey
CISPOLY founded, headquartered in the Beijing Daxing Biomedical Industry Base
CISCER® received NMPA registration (No. 20233400253)
CISENDO® received NMPA registration (No. 20243402610) — the world's first non-invasive endometrial cancer screening launched
CISOVA® received NMPA registration (No. 20253402443) — China's first ovarian cancer methylation test launched; recognized as a Beijing SRDI (Specialized, Refined, Differential, Innovative) Enterprise